vorapaxar

InvivoChem Cat #:V4229CAS #:618385-01-6Purity >=98%

Description: Vorapaxar (also known as SCH 530348), a new anti-platelet drug based on the natural product himbacine, is a thrombin receptor protease-activated receptor (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Vorapaxar was approved in 2014 to help prevent heart attacks and strokes in people who have had a heart attack or have poor blood flow. Vorapaxar acts by inhibiting thrombin-related platelet aggregation. This mechanism is different from other anti-platelet medications such as aspirin and P2Y12 inhibitors. Unlike many other medication, vorapaxar does not affect ADP-mediated platelet aggregation, coagulation parameters, or bleeding time.

Description:

References: J Clin Invest. 2013 Jan; 123(1):206-14.; J Pharm Bioallied Sci. 2016 Apr-Jun; 8(2):98-105.

References:

Related CAS#:705260-08-8 (sulfate)

-20C for 3 years in powder form

Synonym: SCH530348; SCH 530348; SCH-530348
IUPAC/Chemical Name: Ethyl N-[(3R, 3aS, 4S, 4aR, 7R, 8aR, 9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a, 4, 4a, 5, 6, 7, 8, 8a, 9, 9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate
InChi Key: ZBGXUVOIWDMMJE-QHNZEKIYSA-N
InChi Code: InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9, 12-13, 16-17, 20, 23-27H, 3, 10-11, 14-15H2, 1-2H3, (H, 32, 34)/b12-9+/t17-, 20+, 23-, 24-, 25+, 26-, 27+/m1/s1
SMILES Code: O=C(OCC)N[CH](CC1)C[C](C[C]23[H])([H])[C]1([H])[CH](/C=C/C4=NC=C(C5=CC=CC(F)=C5)C=C4)[C]2([H])[CH](C)OC3=O